Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caron A Jacobson

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 26, 2019
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyTania Jain, Merav Bar, Ankit J Kansagra, et al.
The New England Journal of Medicine|December 12, 2017
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
Blood|February 12, 2025
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphomaLaura Samples, Hossein Sadrzadeh, Matthew J Frigault, et al.
The Lancet. Haematology|June 17, 2018
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Frederic Baron, et al.
The Lancet. Haematology|April 28, 2022
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Vishal Bhatnagar, et al.
Blood Advances|August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.
Journal of Hematology & Oncology|December 16, 2023
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma ConsortiumJulie M Vose, Kai Fu, Lu Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F Herrera, Matthew Mei, Lawrence Low, et al.
Cancer Cell|April 13, 2016
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceElizabeth C Townsend, Mark A Murakami, Alexandra Christodoulou, et al.
Cancer Cell|August 2, 2016
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceElizabeth C Townsend, Mark A Murakami, Alexandra Christodoulou, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 26, 2019
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyTania Jain, Merav Bar, Ankit J Kansagra, et al.
The New England Journal of Medicine|December 12, 2017
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
Blood|February 12, 2025
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphomaLaura Samples, Hossein Sadrzadeh, Matthew J Frigault, et al.
The Lancet. Haematology|June 17, 2018
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Frederic Baron, et al.
The Lancet. Haematology|April 28, 2022
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Vishal Bhatnagar, et al.
Blood Advances|August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.
Journal of Hematology & Oncology|December 16, 2023
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma ConsortiumJulie M Vose, Kai Fu, Lu Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F Herrera, Matthew Mei, Lawrence Low, et al.
Cancer Cell|April 13, 2016
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceElizabeth C Townsend, Mark A Murakami, Alexandra Christodoulou, et al.
Cancer Cell|August 2, 2016
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceElizabeth C Townsend, Mark A Murakami, Alexandra Christodoulou, et al.
Pageof 14